Robert Barrow sold $180k of DFTX
Chief Executive Officer at Definium Therapeutics, Inc.. 26,491 shares at an average of $6.80, traded Jun 25, 2025, filed Jun 26, 2025.
Score components
- +25RoleCEO
- +12Trade size$180k at market
- 0Share of holdings soldSold 3.1% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-090428, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 25, 2025 | SOpen-market sale Common Shares10b5-1 | -26,491 | $6.80 | $180k | 830,065 | Jun 26, 2025 |
Related signals
Other insiders at Definium Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | Definium Therapeutics, Inc. | Robert Barrow Chief Executive Officer | $1.2M 31,550 shares | -1% | |
| 27Weak | Definium Therapeutics, Inc. | Brandi Roberts Chief Financial Officer | $123k 3,377 shares | -1% | |
| 28Weak | Definium Therapeutics, Inc. | Mark Sullivan Chief Legal Officer | $514k 14,051 shares | -3% | |
| 20Weak | Definium Therapeutics, Inc. | Matthew T. Wiley Chief Commercial Officer | $113k 3,097 shares | -1% | |
| 26Weak | Definium Therapeutics, Inc. | Daniel Karlin Chief Medical Officer | $397k 10,853 shares | -1% | |
| 26Weak | Definium Therapeutics, Inc. | Robert Barrow Chief Executive Officer | $722k 19,023 shares | -1% | |
| 37Weak | Definium Therapeutics, Inc. | Robert Barrow Chief Executive Officer | $451k 24,431 shares | -3% | |
| 22Weak | Definium Therapeutics, Inc. | Mark Sullivan Chief Legal Officer | $198k 10,702 shares | -4% | |
| 21Weak | Definium Therapeutics, Inc. | Daniel Karlin Chief Medical Officer | $148k 8,018 shares | -2% | |
| 35Weak | Definium Therapeutics, Inc. | Robert Barrow Chief Executive Officer | $339k 25,791 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.